Vatalanib-d4 dihydrochloride(Synonyms: 瓦他拉尼二盐酸盐 d4 (双盐酸盐))

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Vatalanib-d4 dihydrochloride (Synonyms: 瓦他拉尼二盐酸盐 d4 (双盐酸盐))

Vatalanib-d4 (PTK787-d4) dihydrochloride 是 Vatalanib dihydrochloride 的氘代物。Vatalanib dihydrochloride (PTK787 dihydrochloride) 是VEGFR2/KDR的抑制剂，其IC50值为37nM。

Vatalanib-d4 dihydrochloride(Synonyms: 瓦他拉尼二盐酸盐 d4 (双盐酸盐))

Vatalanib-d4 dihydrochloride Chemical Structure

规格 是否有货
1 mg Check price and availability
10 mg Check price and availability

* Please select Quantity before adding items.

生物活性

Vatalanib-d4 (PTK787-d4) dihydrochloride is the deuterium labeled Vatalanib dihydrochloride. Vatalanib (PTK787) dihydrochloride is an inhibitor of VEGFR2/KDR with IC50 of 37 nM[1][2].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

423.76

Formula

C20H13D4Cl3N4
中文名称

瓦他拉尼二盐酸盐 d4 (双盐酸盐)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Wood JM, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60(8

    [3]. Wan J, et al. Local recurrence of small cell lung cancer following radiofrequency ablation is induced by HIF-1α expression in the transition zone. Oncol Rep. 2016 Mar;35(3):1297-308.

    [4]. Murakami M, et al. Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol. 2011, 18(2), 589-596.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

发表回复